IgA Nephropathy Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, and Companies

DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States.

Key Takeaways from the IgA Nephropathy Market Report
• The increase in IgA Nephropathy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the IgA Nephropathy Market is anticipated to witness growth at a considerable CAGR.
• The leading IgA Nephropathy Companies working in the market include Calliditas Therapeutics AB, Travere Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical, and others.
• Promising IgA Nephropathy Therapies in the various stages of development includes RC18 160mg, Telitacicept, Blisibimod, BION-1301, Intravenous Rituximab, and others.
• May 2024:- Alexion Pharmaceuticals- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN). The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
• April 2024:- Chinook Therapeutics Inc.- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study). Approximately 272 patients with eGFR ≥ 30 mL/min/1.73m^2 and with biopsy-proven IgAN will be randomized to receive 600 mg Q2W BION-1301 or a matched placebo for 104 weeks. An additional exploratory cohort, not included in the primary analysis, will be comprised of approximately 20 subjects (10 subjects per arm) with biopsy-confirmed IgAN and eGFR of ≥ 20 to < 30 mL/min/1.73 m^2.

Discover which therapies are expected to grab the IgA Nephropathy Market Share @ IgA Nephropathy Market Outlook- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Overview
IgA nephropathy, also known as Berger's disease, is a kidney disorder that occurs when immunoglobulin A (IgA) deposits build up in the kidneys, causing inflammation that can interfere with the kidneys' ability to filter waste and excess fluids from the blood. IgA is an antibody that helps your body fight infections, but in IgA nephropathy, it's deposited in the kidneys instead of being cleared from the body.

IgA Nephropathy Epidemiology Insights
The epidemiology section of IgA Nephropathy offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving IgA Nephropathy Epidemiology trends @ IgA Nephropathy Epidemiological Insights- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Drugs Market
The IgA Nephropathy Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying IgA Nephropathy signaling in IgA Nephropathy are likely to uncover new therapeutic targets and further expand treatment options for patients.

IgA Nephropathy Treatment Market Landscape
The first medication for treating IgAN to receive FDA approval is TARPEYO (budesonide) delayed-release tablet. It is indicated for IgAN patients at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) =1.5 g/g. In December 2021, the US FDA approved it through an accelerated approval process, acknowledging the pressing need for safe and effective treatments. The recently approved FILSPARI (sparsentan) by Travere Therapeutics, Inc./Vifor Pharma provides the IgAN population with another treatment choice.

To learn more about IgA Nephropathy treatment guidelines, visit @ IgA Nephropathy Treatment Market Landscape- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Market Outlook
The report's outlook on the IgA Nephropathy market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing IgA Nephropathy therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed IgA Nephropathy drug and late-stage pipeline therapy.

It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed IgA Nephropathy market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

IgA Nephropathy Drugs Uptake
The drug chapter of the IgA Nephropathy report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to IgA Nephropathy.

Major IgA Nephropathy Companies
Calliditas Therapeutics AB, Travere Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical, and others.

Learn more about the FDA-approved drugs for IgA Nephropathy @ Drugs for IgA Nephropathy Treatment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the IgA Nephropathy Market Report
• Coverage- 7MM
• IgA Nephropathy Companies- Calliditas Therapeutics AB, Travere Therapeutics Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics Inc., Vera Therapeutics Inc., Otsuka Pharmaceutical, and others.
• IgA Nephropathy Therapies- RC18 160mg, Telitacicept, Blisibimod, BION-1301, Intravenous Rituximab, and others.
• IgA Nephropathy Market Dynamics: IgA Nephropathy Market Drivers and Barriers
• IgA Nephropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about IgA Nephropathy Drugs in development @ IgA Nephropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of IgA Nephropathy (IgAN)
3. Competitive Intelligence Analysis for IgA Nephropathy (IgAN)
4. IgA Nephropathy (IgAN): Market Overview at a Glance
5. IgA Nephropathy (IgAN): Disease Background and Overview
6. Patient Journey
7. IgA Nephropathy (IgAN) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy (IgAN) Unmet Needs
10. Key Endpoints of IgA Nephropathy (IgAN) Treatment
11. IgA Nephropathy (IgAN) Marketed Products
12. IgA Nephropathy (IgAN) Emerging Therapies
13. IgA Nephropathy (IgAN): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of IgA Nephropathy (IgAN)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.